Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

In this Life Sciences Decoded feature, CEO Nigel Theobald breaks down N4 Pharma’s lead RNA program, N4-101—an oral therapeutic for inflammatory bowel disease (IBD) powered by the Nuvec® delivery platform. Designed to target macrophage cells, N4-101 uniquely combines siRNA, mRNA, and a mannose ligand on a single Nuvec® particle to reduce inflammation and enhance immune response.

Watch the full clip below and submit your questions.

N4 101: Unlocking the Science Behind Nuvec®